抗结核复合剂与组合药在肺结核患者发生中断治疗原因的回顾性调查

Reasons of tuberculosis patients discontinuing taking Anti-TB compound and combination drugs

目的固定剂量复合剂（FDC）与板式组合药在肺结核患者发生中断治疗原因的回顾性调查。方法2010年1月至10月湛江市结核病防治所登记的225例初治肺结核病患者，1月至5月的85例为对照组，6月至10月的140例为研究组，对患者治疗过程中断治疗发生原因（漏服、服药困难、药物不良反应）进行对比分析。结果研究组化疗过程中的肺结核患者发生过中断治疗20例（14．29％）、对照组25例（29．41％），两组发生中断治疗比较差异有统计学意义（P〈0．05）。结论肺结核患者采用固定剂量复合剂化疗，患者依从性较好，化疗过程较板式组合药中断治疗发生率低，可在临床继续推广使用。

Objective To survey the reasons of tuberculosis patients discontinuing taking fixed-dose combinations （ FDC ） and combination plate drugs. Methods January to October in 2010, 225 tuberculosis patients primarily cured registered at Tuberculosis Prevention and Control Institution of Zhanjiang. 140 cases registering from May and October were set as a study group, and the rest 85 cases as a control group. The reasons （miss taking medicine, difficulties of taking medicine, adverse drug reactions） causing tuberculosis patients discontinuing their therapy were compared and analyzed. Result 20 cases （ 14.29% ） discontinued the treatment in the study group, and 25 cases （ 29.41% ） in the control group, with a statistical difference （P 〈 0.05）. Conclusions Patients taking fixed-dose compound chemotherapy have better treatment compliance than ones taking combination plate drugs. It is worth being clinically generalized.